×

ChromaDex Reports 5th Consecutive Quarter of Record Revenue as Q2 Ingredients Sales Climb 98%

IRVINE, Calif., Aug. 13, 2015 (GLOBE NEWSWIRE) -- ChromaDex Corp. (OTCQX:CDXC), an innovator of proprietary health, wellness, and nutritional ingredients that creates science-based solutions for dietary supplements, food and beverage, skin care, sports nutrition, and pharmaceutical products announced today record revenue for the second quarter ended July 4, 2015. The report marks the fifth consecutive quarter of record revenues for the Company.

For the three months ended July 4, 2015 ("Q2 2015"), ChromaDex reported record net sales of $6.1 million, an increase of 58% as compared to $3.9 million for the three months ended June 28, 2014 ("Q2 2014"), and a sequential increase of 16% as compared to the three months ended April 4, 2015 ("Q1 2015"). This increase was largely due to increased sales in its ingredients business segment, led by its NIAGEN® branded nicotinamide riboside. The ingredients segment generated record net sales of $3.4 million for Q2 2015, an increase of 98%, compared to $1.7 million for Q2 2014, and a sequential increase of 27% as compared to Q1 2015.

The core standards and services segment also posted its largest quarterly sales ever of $2.4 million for Q2 2015, an increase of 28% compared to $1.9 million for Q2 2014. Net sales for the scientific and regulatory consulting segment were $318K, an increase of 15% as compared to $277K for Q2 2014.

The net loss attributable to common stock holders for Q2 2015 was $315K or ($0.00) per share as compared to a net loss of $1.7 million or ($0.02) per share for Q2 2014. The non-cash, stock based compensation expense related to stock options and other stock-based compensation in Q2 2015 was $507K. Excluding non-cash, share-based compensation expense, which is a "non-GAAP measure," would have the effect of the Company posting a net income of $192K for Q2 2015. As of July 4, 2015, cash, cash equivalents and marketable securities totaled approximately $5.7 million.

Frank Jaksch, Jr., CEO and co-founder of ChromaDex, commented, "Posting our 5th consecutive quarter of record revenue demonstrations the continued momentum we are experiencing in all business segments. Interest from consumer product companies in our patented NIAGEN® nicotinamide riboside is accelerating and we expect to see new products featuring NIAGEN® showing up on shelves of major U.S. retailers in the very near future."

"Given the exciting recent results of the first human clinical study of NR, we are planning a second human clinical NR study to both further validate NR as an effective NAD+ precursor as well as to begin evaluating the therapeutic benefits of increasing NAD+. We also continue to review pharmaceutical indications in which NR alone, or in combination with other actives, may be effective in treating or preventing disease."

Jaksch continued, "Lastly, I am also happy to report that we are in discussions with no less than three Fortune 500 companies with respect to the possibility of several of our patented ingredients, including NIAGEN® nicotinamide riboside and pTeroPure® pterostilbene, being included and featured in a number of branded consumer products within extremely large product categories."

Recent Company highlights include:

Investor Conference Call

ChromaDex management will host an investor conference call to discuss the quarterly results and provide a general business update on Wednesday, August 19th, at 11am EDT. Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

U.S. toll free: 1-866-327-8118

Outside the U.S.: 1-678-509-7526

Conference ID for this call is: 98596925

A webcast replay will be available beginning two hours after the completion of the call on the Investor Relations section of the Company website, www.chromadex.com, and will be archived for a year.

About ChromaDex:

ChromaDex leverages its complementary business units to discover, acquire, develop and commercialize patented and proprietary ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. In addition to our ingredient technologies unit, we also have business units focused on natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (known as Spherix Consulting). As a result of our relationships with leading universities and research institutions, we are able to discover and license early stage, IP-backed ingredient technologies. We then utilize our in-house chemistry, regulatory and safety consulting business units to develop commercially viable ingredients. Our ingredient portfolio is backed with clinical and scientific research, as well as extensive IP protection. Our portfolio of patented ingredient technologies includes NIAGEN® nicotinamide riboside; pTeroPure® pterostilbene; PURENERGY®, a caffeine-pTeroPure® co-crystal; ProC3G®, a natural black rice containing cyanidin-3-glucoside; IMMULINA, a spirulina extract; and Suntava® Purple Corn derived from a proprietary non-GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. To learn more about ChromaDex, please visit www.chromadex.com.

Non-GAAP Financial Measures

In addition to disclosing financial results calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), the earnings release contains non-GAAP financial measures adjusted for non-cash, share-based compensation. Management believes that the non-GAAP measures used in this release provide investors with important perspectives into the Company's ongoing business performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. All financial data is presented on a GAAP basis except where the Company indicates its presentation is on a non-GAAP basis. Set forth below are reconciliations of non-GAAP net income (loss) to the Company's reported GAAP net income (loss).

Forward-Looking Statements:

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects", "anticipates", "intends", "estimates", "plans", "potential", "possible", "probable", "believes", "seeks", "may", "will", "should", "could" or the negative of such terms or other similar expressions. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company's business. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's Annual Report on Form 10-K for the fiscal year ended January 3, 2015, the Company's Quarterly Reports on Form 10-Q, the Company's Current Reports on Form 8-K and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

ChromaDex Corporation and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
For the Three Month Periods Ended July 4, 2015 and June 28, 2014
July 4, 2015 June 28, 2014
Sales, net $ 6,101,380 $ 3,856,154
Cost of sales 3,630,688 2,457,388
Gross profit 2,470,692 1,398,766
Operating expenses:
Sales and marketing 639,748 571,548
General and administrative 2,015,004 2,468,646
Operating expenses 2,654,752 3,040,194
Operating loss (184,060) (1,641,428)
Nonoperating income (expense):
Interest income 645 305
Interest expense (131,777) (12,019)
Nonoperating expenses (131,132) (11,714)
Net loss $ (315,192) $ (1,653,142)
Basic and Diluted loss per common share $ (0.00) $ (0.02)
Basic and Diluted weighted average common shares outstanding 107,409,894 106,185,584
See Notes to Condensed Consolidated Financial Statements.
Consolidated Statements of Operations
(US GAAP)
Effects of Non-cash Charges associated with
Share-based Compensation Expense
Consolidated Statements of Operations
Excluding Share-based Compensation (Non-GAAP Presentation)
For the Three Month Periods Ended July 4, 2015 and June 28, 2014 For the Three Month Periods Ended July 4, 2015 and June 28, 2014 For the Three Month Periods Ended July 4, 2015 and June 28, 2014
July 4,
2015
June 28,
2014
July 4,
2015
June 28, 2014 July 4,
2015
June 28, 2014
Sales $ 6,101,380 $ 3,856,154 Sales $ -- $ -- Sales $ 6,101,380 $ 3,856,154
Cost of sales 3,630,688 2,457,388 Cost of sales -- -- Cost of sales 3,630,688 2,457,388
Gross profit 2,470,692 1,398,766 Gross profit -- -- Gross profit 2,470,692 1,398,766
Operating expenses: Operating expenses: Operating expenses:
Sales and marketing 639,748 571,548 Sales and marketing -- -- Sales and marketing 639,748 571,548
General and administrative 2,015,004 2,468,646 General and administrative (507,268) (1,036,608) General and administrative 1,507,736 1,432,038
Operating expenses 2,654,752 3,040,194 Operating expenses (507,268) (1,036,608) Operating expenses 2,147,484 2,003,586
Operating loss (184,060) (1,641,428) Operating income 507,268 1,036,608 Operating income (loss) 323,208 (604,820)
Nonoperating income (expense): Nonoperating income: Nonoperating income (expense):
Interest income 645 305 Interest income -- -- Interest income 645 305
Interest expense (131,777) (12,019) Interest expense -- -- Interest expense (131,777) (12,019)
Nonoperating expense (131,132) (11,714) Nonoperating income -- -- Nonoperating expense (131,132) (11,714)
Net loss $ (315,192) $ (1,653,142) Net income $ 507,268 $ 1,036,608 Net income (loss) $ 192,076 $ (616,534)
Basic and Diluted loss per common share $ (0.00) $ (0.02) Basic and Diluted income per common share $ 0.00 $ 0.01 Basic and Diluted loss per common share $ 0.00 $ (0.01)
Basic and Diluted weighted average common shares outstanding 107,409,894 106,185,584 Basic and Diluted weighted average common shares outstanding 107,409,894 106,185,584 Basic and Diluted weighted average common shares outstanding 107,409,894 106,185,584

CONTACT: ChromaDex Investor Contacts: The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 bprag@delmarconsulting.com or ChromaDex Contact: Andrew Johnson Director of Investor Relations 949-419-0288 andrewj@chromadex.com

Source:ChromaDex Corp